The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: An analysis of RTOG data

Lung Cancer

Volumn 41, Issue 2, 2003, Pages 207-214

  Emami, Bahman ^a   Mirkovic, Nena ^a   Scott, Charles ^b   Byhardt, Roger ^c   Graham, Mary V ^d   Andras, E James ^e   John, Madhu ^f   Herskovic, Arnold ^g   Urtasun, Raul ^h   Asbell, Sucha O ⁱ   Perez, Carlos A ^j   Cox, James ^k  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Phelps County Regional Medical Center   (United States)

^e Radiation Oncology Center   (United States)

^f Cancer Center at St Agnes   (United States)

^g NORTHWEST COMMUNITY HOSPITAL   (United States)

^h CROSS CANCER INSTITUTE   (Canada)

ⁱ ALBERT EINSTEIN MEDICAL CENTER   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Field borders; In field progression; Non small cell lung cancer; Radiotherapy; Regional nodes; Survival

Indexed keywords

ADULT; AGED; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DOSIMETRY; HUMAN; LUNG HILUS; LUNG NON SMALL CELL CANCER; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MEDIASTINUM LYMPH NODE; PRIORITY JOURNAL; RADIATION DOSE; WEIGHT REDUCTION;

EID: 0038166891     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00228-9     Document Type: Conference Paper

References (27)

1. Perez C.A., Pajak T.F., Rubin P., et al. Long term observation of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiation therapy. Report by the Radiation Therapy Oncology group. Cancer. 59:1987;1874-1881.
2. Le Chevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer; first analysis of a randomized trial in 353 patients. J. Natl. Cancer Inst. 83:(6):1991;417-423.
3. Fletcher G. Clinical dose-response curve of human malignant epithelial tumors. Br. J. Radiol. 46:1973;1.
4. Martel M.K., Ten Haken R.K., Hazuka M.B., Kessler M.L., Strawderman M., Turrisi A.T., et al. Estimation of tumor control probability model parameters from 3-D dose distribution of non-small cell lung cancer patients. Lung Cancer. 24:(1):1999;31-37.
5. Perez C.A., Stanley K., Rubin P., Kramer S., Brady L., Perez-Tamayo R., et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer. 45:(11):1980;2744-2753.
6. Willner J., Baier K., Caragiani E., Tschammler A., Flentje M. Dose, volume and tumor control prediction in primary radiotherapy of non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 52:(2):2002;382-389.
7. Cox J.D., Azarnia N., Byhardt R.W., Shin K.H., Emami B., Pajak T. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0-79.2 Gy: possible survival benefit with (69.6 Gy in favorable patients with radiation oncology group stage III non-small-cell lung carcinoma: report of radiation therapy oncology group 83-11. J. Clin. Oncol. 8:(9):1990;1543-1555.
8. Saunders M., Dische S., Barrett A., et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer. Mature data from a randomized multicentre trial. Radiother. Oncol. 50:1999;161-165.
9. Schaake-Koning C., van der Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. New Engl. J. Med. 326:1992;524-530.
10. Perez C.A., Bauer M., Edelstein S., Gillespie B.W., Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int. J. Radiat. Oncol. Biol. Phys. 12:(4):1986;539-547.
11. Byhardt R.W., Martin L., Pajak T.F., Shin K.H., Emami B., Cox J.D. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC) - analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int. J. Radiat. Oncol. Biol. Phys. 27:1993;537-544.
12. Graham A.N., Chan K.J., Pastorino U., Goldstraw P. Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 117:(2):1999;246-251.
13. Sugi K., Nawata K., Fujita N., et al. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell-lung cancer less than 2 cm in diameter. World J. Surg. 22:1998;290-294.
14. Izbicki J.R., Passlick B., Pantel K., et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer. Ann. Surg. 227:1998;138-144.
15. Wu Y.L., Huang Z.F., Wang S.Y., Yang X.N., Ou W. A randomized trial of systematic nodal dissection in respectable non-small cell lung cancer. Lung Cancer. 36:2002;1-6.
16. Pu A.T., Harrison A.S., Robertson J.M., et al. The toxicity of elective nodal irradiation in the definitive treatment of non-small cell carcinoma of the lung (abstract). Int. J. Radiat. Oncol. Biol. Phys. 39:1997;S196.
17. Perez C.A., Bauer M., Emami B., Byhardt R., Brady L.W., Dogett R.L.S., et al. Thoracic irradiation with or without levamisole (NSC#177023) in unresectable non-small cell carcinoma of the lung: A phase III randomized trial of the RTOG. Int. J. Radiat. Oncol. Biol. Phys. 15:1988;1337-1346.
18. Simpson J.R., Bauer M., Perez C.A., Wasserman T.H., Emami B., Doggett R.L.S., et al. Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: report of an RTOG prospective randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 16:1989;1483-1491.
19. Byhardt R.W., Pajak T.F., Emami B., Herskovic A., Doggett R.S., Olsen L.A. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07. Int. J. Radiat. Oncol. Biol. Phys. 26:1992;459-468.
20. Graham M.V., Purdy J.A., Emami B., Harms W., Bosch W., Lockett M.A., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). J. Radiat. Oncol. Biol. Phys. 45:(2):1999;323-329.
21. Kwa S.L.S., Lebesque J.V., Theuws J.C.M., Marks L.B., Munley M.T., Bentel G., et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int. J. Radiat. Oncol. Biol. Phys. 42:(1):1998;1-9.
22. Martel M.K., Ten Haken R.K., Hazuka M.B., Turrisi A.T., Fraas B.A., Lichter A.S. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 28:(3):1994;777-779.
23. Rosenzweig K.E., Sim S.E., Mychalczak B., Braban L.E., Schindelhein R., Leibel S.A. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;681-685.
24. Hayman J.A., Martel M.K., Ten Haken R.K., Normolle D.P., Todd R.F. III, Littles J.F., et al. Dose escalation in non-small cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J. Clin. Oncol. 19:(1):2001;127-136.
25. Senan S., Burger S., Samson M.J., Klaveren R.J., Swat Oei S., van Sornses de Koste J., et al. Can elective nodal irradiation be omitted in stage III non-small cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-filed radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 54:(4):2002;999-1006.
26. Cheung P.C.F., Mackillop W.J., Dixon P., Brundage M.D., Youssef Y.M., Zhou S. Involved filed radiotherapy alone for early stage non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 48:(3):2000;703-710.
27. Krol A.D., Aussems P., Noordijk E.M., Hermans J., Leer J.W. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation. Int. J. Radiat. Oncol. Biol. Phys. 34:(2):1996;297-302.